Table 4 Cumulated hospital days during induction and consolidation therapy, median (IQR).

From: Long-term outcome of children with acute promyelocytic leukemia: a randomized study of oral versus intravenous arsenic by SCCLG-APL group

 

Hospital days

ATO

RIF

p

High-risk

68.0 (45.0,77.5)

44.5 (40.0,63.0)

0.048

Intermediate-risk

64.0 (46.5,73.5)

39.0 (28.0,49.0)

0.000

Low-risk

65.0 (56.0,76.5)

34.0 (24.0,47.5)

0.000

  1. Low-risk APL WBC ≤ 10 × 109/L and PLT ≥ 40 × 109/L, intermediate-risk WBC ≤ 10 × 109/L and PLT < 40 × 109/L, high-risk WBC > 10 × 109/L at diagnosis.
Back to article page